Antiphospholipid syndrome medical therapy: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Antiphospholipid syndrome}} {{CMG}} ==Overview== ==Treatment== The cornerstone of therapy for symptomatic antiphospholipid syndrome hinges on platelet inhibition ...")
 
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
==Treatment==
The cornerstone of therapy for symptomatic antiphospholipid syndrome hinges on platelet inhibition with or without [[anticoagulation]]. Platelet inhibition is often achieved with [[aspirin]], while [[warfarin]] and [[heparin]] are the mainstays of anticoagulation. Generally there is no indication for primary prophylaxis. Immunosuppression, the use of [[intravenous immunoglobulin]], and [[plasmapheresis]] have also been used with modest success.
The cornerstone of therapy for symptomatic antiphospholipid syndrome hinges on platelet inhibition with or without [[anticoagulation]]. Platelet inhibition is often achieved with [[aspirin]], while [[warfarin]] and [[heparin]] are the mainstays of anticoagulation. Generally there is no indication for primary prophylaxis. Immunosuppression, the use of [[intravenous immunoglobulin]], and [[plasmapheresis]] have also been used with modest success.
 
==Medical Therapy==
===Anticoagulation===
===Anticoagulation===
When anticoagulation with warfarin is pursued, some authors recommend a goal INR of 3.0-4.0.<ref>{{cite journal |author=Horton JD, Bushwick BM |title=Warfarin therapy: evolving strategies in anticoagulation |journal=American family physician |volume=59 |issue=3 |pages=635-646 |year=1999 |pmid=10029789 |doi=}}</ref> However, the current standard of care targets a therapeutic INR of 2.0-3.0 following initial venous thromboembolism, and an INR >3.0 for an arterial event or venous thrombosis refractory to anticoagulation.<ref name="pmid18050167">{{cite journal |author=Ruiz-Irastorza G, Hunt BJ, Khamashta MA |title=A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies |journal=Arthritis and Rheumatism |volume=57 |issue=8 |pages=1487–95 |year=2007 |month=December |pmid=18050167 |doi=10.1002/art.23109 |url=http://dx.doi.org/10.1002/art.23109}}</ref> Khamashta et al in a study of 147 patients with usual antiphopholipid antibody syndrome showed a low rate of recurrent thrombosis in patients with INR >3, with a risk of 7.1% bleeding complications per patient year (a third of which were serious).
When anticoagulation with warfarin is pursued, some authors recommend a goal INR of 3.0-4.0.<ref>{{cite journal |author=Horton JD, Bushwick BM |title=Warfarin therapy: evolving strategies in anticoagulation |journal=American family physician |volume=59 |issue=3 |pages=635-646 |year=1999 |pmid=10029789 |doi=}}</ref> However, the current standard of care targets a therapeutic INR of 2.0-3.0 following initial venous thromboembolism, and an INR >3.0 for an arterial event or venous thrombosis refractory to anticoagulation.<ref name="pmid18050167">{{cite journal |author=Ruiz-Irastorza G, Hunt BJ, Khamashta MA |title=A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies |journal=Arthritis and Rheumatism |volume=57 |issue=8 |pages=1487–95 |year=2007 |month=December |pmid=18050167 |doi=10.1002/art.23109 |url=http://dx.doi.org/10.1002/art.23109}}</ref> Khamashta et al in a study of 147 patients with usual antiphopholipid antibody syndrome showed a low rate of recurrent thrombosis in patients with INR >3, with a risk of 7.1% bleeding complications per patient year (a third of which were serious).
Line 31: Line 30:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Disease]]
[[Category:Rheumatology]]
[[Category:Hematology]]
[[Category:Autoimmune diseases]]
[[Category:Neurology]]
[[Category:Obstetrics]]
[[Category:Syndromes]]

Revision as of 13:24, 29 October 2012

Antiphospholipid syndrome Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Antiphospholipid syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Antiphospholipid syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Antiphospholipid syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Antiphospholipid syndrome medical therapy

CDC on Antiphospholipid syndrome medical therapy

Antiphospholipid syndrome medical therapy in the news

Blogs on Antiphospholipid syndrome medical therapy

Directions to Hospitals Treating Antiphospholipid syndrome

Risk calculators and risk factors for Antiphospholipid syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The cornerstone of therapy for symptomatic antiphospholipid syndrome hinges on platelet inhibition with or without anticoagulation. Platelet inhibition is often achieved with aspirin, while warfarin and heparin are the mainstays of anticoagulation. Generally there is no indication for primary prophylaxis. Immunosuppression, the use of intravenous immunoglobulin, and plasmapheresis have also been used with modest success.

Medical Therapy

Anticoagulation

When anticoagulation with warfarin is pursued, some authors recommend a goal INR of 3.0-4.0.[1] However, the current standard of care targets a therapeutic INR of 2.0-3.0 following initial venous thromboembolism, and an INR >3.0 for an arterial event or venous thrombosis refractory to anticoagulation.[2] Khamashta et al in a study of 147 patients with usual antiphopholipid antibody syndrome showed a low rate of recurrent thrombosis in patients with INR >3, with a risk of 7.1% bleeding complications per patient year (a third of which were serious).

Anticoagulation in pregnancy

During pregnancy, low molecular weight heparin and low-dose aspirin are used to avoid warfarin's teratogenicity. Women with recurrent miscarriage are often advised to take aspirin and to start low molecular weight heparin treatment after missing a menstrual cycle.

Platelet inhibition

Aspirin is frequently added to a regimen of chronic anticoagulation, particularly when patients experience recurrent thrombosis despite therapeutic aticoagulation. However data demonstrating additive benefit are lacking.

Immunosuppression

It is not clear that immunosuppression is beneficial, particularly in patients who do not have an underlying autoimmune process. Nevertheless, immunosuppression is often tried in patients who have failed usual anticoagulation. Steroids, for example prednisone 1 mg/kg (or equivalent), has been used with moderate success. Pulse solumedrol IV 1 g/d for 3 days is an alternative regimen. Cyclophosphamide, either oral or pulse IV, has demonstrated modest utility.

Other, more desperate interventions include intravenous immunoglobulin and plasmapheresis. The latter has been shown via case reports to have efficacy in patients who have failed other interventions.

Treatment of catastrophic disease

Optimal treatment has not been clearly defined in this condition. We are limited to data from small case report studies. These patients often display a fulminant course with rapid multiorgan system failure, so multiple interventions are often desperately tried in hopes that the patient might respond to something and survive.

References

  1. Horton JD, Bushwick BM (1999). "Warfarin therapy: evolving strategies in anticoagulation". American family physician. 59 (3): 635–646. PMID 10029789.
  2. Ruiz-Irastorza G, Hunt BJ, Khamashta MA (2007). "A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies". Arthritis and Rheumatism. 57 (8): 1487–95. doi:10.1002/art.23109. PMID 18050167. Unknown parameter |month= ignored (help)

Template:WH Template:WS